TP53, TERT (promoter), and CTNNB1 are dominant mutational driver cancer genes, which account for 21–31 %, 44–65 %, and 27–40 % of patients with HCC (Yang et al., 2019b; Llovet et al., 2021). Here, TP53 is linked to cancer.